As therapy for chronic lymphocytic leukemia (CLL) continues to evolve, 2025 brought research, regulatory news, and expert ...

The CLL17 trial showed noninferiority of fixed-duration regimens compared to continuous BTK inhibitor therapy, highlighting ...

Interim safety summary of alemtuzumab vs. chlorambucil as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL) This is an ASCO Meeting Abstract from the 2004 ...

Findings showed pirtobrutinib was noninferior to ibrutinib in both the pre-treated and intent-to-treat populations for the endpoint of ORR. Topline data were announced from a head-to-head phase 3 ...

Please provide your email address to receive an email when new articles are posted on . Novel targeted therapies have become standard treatment for chronic lymphocytic leukemia due to their ability to ...

Abbvie ($ABBV) announced an update on their ongoing clinical study. AbbVie, in collaboration with Hoffmann-La Roche and the German CLL Study ...

Developments in chronic lymphocytic leukemia (CLL) this year included the first CAR T-cell therapy approval for the chronic blood cancer, potential treatments for Richter transformation, and ...

The FDA granted accelerated approval to lisocabtagene maraleucel (liso-cel, Breyanzi) for pretreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), drugmaker Bristol Myers ...

As I visit the cancer center for chemotherapy to treat my CLL, I can’t help but take note of how different cancer may look in each person. Having chemotherapy for my chronic lymphocytic leukemia is ...

Like a creature from a science fiction movie, chronic lymphocytic leukemia (CLL) can be a shape-shifter. In a small number of cases, patients with CLL will develop lymphoma, a complication known as ...

Truxima (rituximab-abbs) is prescribed to treat certain cancers and immune system conditions. The drug is a liquid that a healthcare professional injects into a vein. Doctors determine the dosing ...